Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in Neoadjuvant Treatment of Cervical Cancer
CTR20220443Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Mar 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Cervical Cancer (CC), cervical squamous cell carcinoma (CSCC), sponsored by Akeso, Inc.. Started Mar 2022; status: terminated.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on CTR20220443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220443.